# Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

> **NCT04822337** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 70 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

## Key facts

- **NCT ID:** NCT04822337
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-19
- **Primary completion:** 2029-04
- **Final completion:** 2032-11
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04822337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04822337, "Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04822337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*